Collegium Prices $70M IPO As Another Biotech Postpones
Venture capital-backed Collegium Pharmaceutical Inc., an early-stage biotechnology company developing a painkiller aimed at challenging market-leader Oxycontin, raised $70 million in an initial public offering Thursday that priced shares at the...To view the full article, register now.
Already a subscriber? Click here to view full article